Optune Lua's NSCLC brain metastases PMA decision will test whether TTFields can expand beyond its Optune Gio base into a larger lung cancer population

Bull

FDA approval would validate the Phase 3 METIS trial data and open a new commercial indication for Optune Lua in NSCLC brain metastases — a population with limited systemic treatment options and historically poor outcomes. This would meaningfully expand the addressable patient population beyond the existing metastatic NSCLC approvals, provide a differentiated CNS-specific label, and demonstrate the platform's extensibility at a time when the TRIDENT GBM failure has raised questions about TTFields' breadth.

Bear

The most likely failure modes are FDA requesting additional data or issuing a complete response letter citing insufficient evidence of clinical benefit from METIS, concerns about the magnitude of effect size, or labeling disputes that narrow the indicated population to the point of limiting commercial utility. The TRIDENT failure in GBM — also a CNS TTFields application — could heighten FDA scrutiny around the mechanism's CNS efficacy and create a more skeptical review environment for this application.